Medicofarma Biotech (WAR:MDB) Moat Score: 0/10 (As of Jul. 02, 2026)


WAR:MDB Medicofarma Biotech SA WAR:MDB
33 GF Score
Price zł0.43
GF Value zł0.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medicofarma Biotech Moat Score?

Medicofarma Biotech has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Medicofarma Biotech has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Medicofarma Biotech might have No Moat - No discernible moat.

Medicofarma Biotech  (WAR:MDB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Medicofarma Biotech Moat Score Related Terms

WAR:MDB
33GF Score
Medicofarma Biotech SA WAR:MDB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?

Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued. The current stock price of zł0.43 is trading 768% above its estimated GF Value™ of zł0.05. GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.

Key valuation signals for WAR:MDB:

  • Moat Score: 0
  • GF Value™: zł0.05 vs. price of zł0.43 (768% above fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicofarma Biotech Business Description

Address ul. Sokołowska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
33GF Score

Get the complete analysis for WAR:MDB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.43
Price
zł0.05
GF Value